Valantine Hannah's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Feb 13, 2024
- Accession no.
- 0000950170-24-014523
- Filed
- Feb 13, 2024
- Trade date
- Dec 28, 2021
- Filing delay
- 777 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $44.5K. It was filed 777 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0000950170-25-091756 (Jun 30, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valantine HannahCIK 0001855608 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +1,891 | $13.18 | +$24,923.38 | 1,891 | Indirect | |
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +1,542 | $12.68 | +$19,552.56 | 3,433 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.